Maravai LifeSciences Reports Second Quarter 2025 Financial Results
Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings
What is the expected impact on dividend policy or share repurchase plans following the cost reductions?
What are analysts’ consensus estimates for Q3 and FY 2025, and how does the new guidance compare?
How might the cost‑saving initiatives influence the company’s competitive positioning in the market?
26 days ago